Despite the availability of publicly funded hepatitis C (HCV) treatment in Canada, treatment
gaps persist, particularly among people who inject drugs. We estimate correlates of HCV …

Background Despite high burden of Hepatitis C (HCV) among people who inject drugs,
significant barriers to care persist. The aim of this study was to evaluate the provision of …

Background People who inject drugs (PWID) are disproportionately affected by hepatitis C
virus (HCV). Data tracking the engagement of PWID in the continuum of HCV care are …

Background Understanding factors associated with engagement across the hepatitis C virus
(HCV) cascade of care (CoC) among people who inject drugs (PWID) is critical for …

Background: Chronic hepatitis C virus (HCV) infection is common among people who inject
drugs (PWID) and is associated with morbidity and premature death. Although HCV can be …

Background Treatment of hepatitis c virus (HCV) with direct-acting-antivirals (DAAs) by
family physicians in primary care and addiction settings may allow treatment expansion to …

Background Despite the key role that people who inject drugs (PWID) play in the hepatitis C
virus (HCV) epidemic, HCV treatment rates among this population have been historically …

Background With the advent of direct acting antiviral (DAA) therapies for the treatment of
hepatitis C virus (HCV), the World Health Organization recommended a goal to eliminate …

Abstract Introduction Hepatitis C (HCV) infection in England primarily affects people who
inject drugs (PWID). We describe persons HCV tested, estimate incidence and establish the …

Background To inform the development of updated World Health Organization (WHO)
guidelines on simplified service delivery for HCV infection, a global survey was undertaken …